FDA Calendar

PDUFA dates and FDA Panel Review dates are very important because they are make or break events for biostocks when the decisions are announced. Also, usually biostocks experience a run-up going into the scheduled decision/review dates. So having prior knowledge of the catalysts goes a long way toward maximizing profit or minimizing loss while trading volatile biotech stocks.
Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.

Get in-depth analysis and insight on investing in the high-stakes biotech and pharma sectors. Check out our premium biotech research product and our biotech home page.
Company Name
Adamas Pharmaceuticals Inc
FDA decision on GOCOVRI as treatment for OFF episodes in Parkinson’s disease patients receiving levodopa-based therapy
Aurinia Pharmaceuticals Inc.
Voclosporin (NDA)
FDA decision on Voclosporin for the treatment of lupus nephritis
Merck & Co Inc.
FDA decision on Vericiguat in Patients with symptomatic chronic Heart Failure and Reduced Ejection Fraction
scPharmaceuticals Inc.
FUROSCIX (Resubmitted NDA)
FDA decision on FUROSCIX or the treatment of worsening heart failure due to congestion
Athenex, Inc.
Tirbanibulin Ointment (NDA)
FDA decision on Tirbanibulin Ointment for the treatment of actinic keratosis
Osmotica Pharmaceutical Corp
Arbaclofen ER (Resubmitted NDA)
FDA decision on Arbaclofen ER for the treatment of spasticity in patients with MS
Mylan N.V.
MYL-1402O (BLA)
FDA decision on MYL-1402O, a proposed biosimilar to Avastin
Urovant Sciences Ltd.
Vibegron (NDA)
FDA decision on Vibegron for the treatment of overactive bladder
AstraZeneca PLC
Roxadustat (NDA)
FDA decision on Roxadustat for the treatment of anemia of chronic kidney disease (CKD), in both non-dialysis-dependent and dialysis-dependent patients
Myovant Sciences Ltd
Relugolix (NDA)
FDA decision on once-daily, oral Relugolix for the treatment of men with advanced prostate cancer
FibroGen Inc.
Roxadustat (NDA)
FDA decision on Roxadustat for the treatment of anemia of chronic kidney disease (CKD), in both non-dialysis-dependent and dialysis-dependent patients
Amgen Inc.
ABP 798 (BLA)
FDA decision on ABP 798 (biosimilar rituximab) for Non-Hodgkin's lymphoma and Rheumatoid arthritis
MacroGenics Inc.
Margetuximab (BLA)
FDA decision on Margetuximab for the treatment of patients with metastatic HER2-positive breast cancer in combination with chemotherapy
Alnylam Pharmaceuticals Inc.
Lumasiran (NDA)
FDA decision on Lumasiran for the treatment of primary hyperoxaluria type 1 (PH1)
Biocryst Pharmaceuticals Inc
Berotralstat (BCX7353) (NDA)
FDA decision on berotralstat for prevention of hereditary angioedema (HAE) attacks

ALSO READ - COVID-19 Drugs In Development Calendar which lists Companies that are in Race to find a Treatment or Vaccine for the Novel Coronavirus.

Buy this Content
The total number of confirmed coronavirus cases in the United States crossed 5 million Sunday. One fifth of these cases, or a million, were reported in just more than two weeks. However, a sharp drop in new cases and deaths were reported at the weekend. An additional 46,935 coronavirus infections were reported in the last 24 hours, taking the total number of cases in the country to 5044864, as p
Zyus Life Sciences Inc. said that it received a medical sales license from Health Canada, effective July 31. The Canada-based company noted that the medical sales license allows it to enroll medical cannabis patients as it works to advance the development, formulation, and application of phyto-therapeutics. Zyus...
Centers for Disease Control and Prevention warned that swallowing hand sanitizers that contain methanol can cause permanent blindness or death, if not treated. The federal health agency called on people to immediately discontinue use of hand sanitizers recalled by U.S. Food and Drug Administration. Some of the hand sanitizers that FDA banned from consumption in the country include the following:
Read More